ESMO Deep Dive: First-Line Therapy for HRD-Negative Advanced Ovarian Cancer 2026
The ESMO Deep Dive: First-Line Therapy for HRD-Negative Advanced Ovarian Cancer 2026 webinar, organized by the European Society for Medical Oncology (ESMO), will take place live on 2 September 2026 at 18:30 CEST. The session will examine the reliability of current HRD testing, the role of PARP inhibitors in maintenance therapy, and the emerging potential […]